| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger Corp. (NASDAQ:KBLM) (NASDAQ:KBLMR) (NASDAQ:KBLMW), announces the availability of a broadcast titled “Banking on the Next Blockbuster Drug.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please click here.
180 Life Sciences Corp. was started by four world-renowned scientists and entrepreneurs who invested their own money to start the company. These scientists own the majority of the equity in 180 Life Sciences and aren’t selling any in the pending merger with KBL Merger Corp. (NASDAQ:KBLM), slated to close before year-end. KBL Merger Corp. (a blank-check company) is the fourth Special Purpose Acquisition Company (SPAC) run by CEO Marlene Krauss, M.D.
KBLM raised $115 million with the goal of identifying and merging with a company with a strong value proposition. Krauss is an innovator and pioneer in SPACs and has invested more than $1 billion through three institutional venture capital funds, numerous IPOs and three prior SPACs. She is one of the first people to obtain both an M.D. and MBA degree from Harvard and one of the few physicians to lead a SPAC. Krauss has always had a passion for healthcare and innovative companies with blockbuster potential and, after eliminating dozens of other companies, signed a definitive agreement to acquire 180 Life Sciences Corp.
